---
title: "William Blair’s Vazquez Maintains Buy on iRhythm, Citing Attractive Valuation and Long-Term Growth Upside from Zio MCT Launch"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292532877.md"
description: "William Blair analyst Brandon Vazquez maintains a Buy rating on iRhythm (IRTC), citing attractive valuation and long-term growth potential from the Zio MCT launch. He views the removal from the Conviction List as procedural, not fundamental. The stock trades at ~4x 2027 sales estimates with strong risk-reward. Citi also reiterated a Buy rating with a $157 price target on July 8."
datetime: "2026-07-13T21:15:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292532877.md)
  - [en](https://longbridge.com/en/news/292532877.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292532877.md)
generator: "portal-rs"
---

# William Blair’s Vazquez Maintains Buy on iRhythm, Citing Attractive Valuation and Long-Term Growth Upside from Zio MCT Launch

William Blair analyst Brandon Vazquez has maintained their bullish stance on IRTC stock, giving a Buy rating on July 8.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Brandon Vazquez has given his Buy rating due to a combination of factors related to iRhythm’s long‑term growth outlook and valuation. He notes that the firm’s removal from William Blair’s Conviction List is purely the result of a six‑month time‑horizon rule for that list, not a shift in his positive view of the company’s fundamentals.

He continues to expect meaningful upside from the eventual launch of Zio MCT, despite near‑term uncertainty around its timing, and believes the product can materially accelerate growth through 2027 once commercialized. With the stock trading at roughly four times his 2027 sales estimate and supported by a solid core business and expanding channel opportunities, he sees the risk‑reward as attractive and therefore maintains an Outperform (Buy) stance.

In another report released on July 8, Citi also reiterated a Buy rating on the stock with a $157.00 price target.

### Related Stocks

- [IRTC.US](https://longbridge.com/en/quote/IRTC.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Costco (COST) Receives a Buy from Evercore ISI](https://longbridge.com/en/news/297937577.md)
- [Netflix has no dividend. Here's why long-term investors should own it anyway.](https://longbridge.com/en/news/298217144.md)
- [Canaccord Genuity Reaffirms Their Buy Rating on Many Peaks Gold Ltd. (MPK)](https://longbridge.com/en/news/297968765.md)
- [Is Argan (AGX) A Bargain As Strong Earnings Raise Fresh Valuation Questions?](https://longbridge.com/en/news/297882822.md)
- [Ciena: Buy on Post-Earnings Weakness as Analyst Trims Price Target to $520 on Reset Expectations](https://longbridge.com/en/news/297950545.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**